

# Continuing Education

## Rheumatoid Arthritis: Disease Characteristics and Comparisons of Novel Treatments

### **Authors:**

Callie Baker Koyle  
Pharm.D., 2016  
Harrison School of Pharmacy, Auburn University

Kelsey Douglas  
Pharm.D., 2016  
Harrison School of Pharmacy, Auburn University

Jacob Kenney  
Pharm.D., 2016  
Harrison School of Pharmacy, Auburn University

### **Corresponding Author:**

Bernie Olin, Pharm.D.  
Associate Clinical Professor and Director  
Drug Information and Learning Resource Center  
Harrison School of Pharmacy, Auburn University

**Universal Activity #: 0178-0000-16-106-H01-P | 1.5 contact hours (.15 CEUs)**

**Initial Release Date: December 2, 2016 | Expires: September 30, 2018**

- Which of the following drugs work by blocking the actions of IL-6?
    - Etanercept (Embrel®)
    - Anakinra (Kineret®)
    - Golimumab (Simponi®)
    - Tocilizumab (Actemra®)
  - Which laboratory finding is not typically associated with rheumatoid arthritis?
    - Elevated CRP
    - Increased SCr
    - Leukocytosis
    - Leukopenia
  - Which ACR/EULAR score is associated with definite rheumatoid arthritis?
    - $\geq 6$
    - $< 6$
    - 0
    - 10
  - Which radiographic findings are associated with rheumatoid arthritis?
    - Decreased joint space
    - Osteopenia
    - Joint erosions
    - All of the above
  - Which marker is the most specific to rheumatoid arthritis?
    - Rheumatoid factor (RF)
    - Interleukin-6 (IL-6)
    - Erythrocyte sedimentation rate (ESR)
    - Anticitrullinated peptide antibody (ACPA)
  - Which of the following is most commonly associated with tocilizumab (Actemra®)?
    - Nausea and vomiting
    - Anemia
    - Elevated transaminase (ALT/AST) levels
    - Thrombocytosis
  - One of the most common symptoms of rheumatoid arthritis is morning stiffness. How long does morning stiffness usually last in individuals with RA?
    - $>15$  minutes
    - $>30$  minutes
    - $>1$  hour
    - $>2$  hours
  - Joint involvement in rheumatoid arthritis patients is commonly presented as symmetrical
    - True
    - False
  - What joints are commonly involved in RA?
    - Hands
    - Wrists
    - Feet
    - All of the above
  - What is the mechanism of action of golimumab (Simponi®)
    - Blocks the IL-6 receptor
    - Inhibits TNF-alpha
    - Inhibits JAK kinase receptors
    - Both A and B
  - What is a common side effect of golimumab (Simponi®)
    - Upper respiratory tract infections
    - Increased levels of cholesterol
    - Peripheral edema
    - All of the above
  - All of these are environmental factors that can contribute to rheumatoid arthritis except?
    - Smoking
    - Obesity
    - Pulmonary disease
    - Periodontal disease
-

**QUIZ – RHEUMATOID ARTHRITIS | ACPE#: 0178-0000-16-106-H01-P**

13. Which of the drugs listed below are JAK Kinase inhibitors?
- a. Tofactinib (Xeljanz®)
  - b. Golimumab (Simponi®)
  - c. Tocilizumab (Actemra®)
  - d. Methotrexate (Trexall®)
14. Which of the following does not correctly describe rheumatoid arthritis as a disease state?
- a. Chronic
  - b. Autoimmune
  - c. Inflammatory
  - d. Hemorrhagic
15. All of these are disadvantages of the drug tofacitinib (Xeljanz®) except?
- a. Oral
  - b. Increased levels of creatinine
  - c. Risk of causing herpes zoster
  - d. Decreased levels of neutrophils
-

**Participant Information:**

AL License # \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

E-mail \_\_\_\_\_

NABP e-Profile # \_\_\_\_\_

MM/DD (month/day of birth) \_\_\_\_\_

How long did it take you to read the article and complete this test?

\_\_\_\_\_ hours \_\_\_\_\_ minutes

My signature certifies that I have independently taken this CE examination.

\_\_\_\_\_

CE Assessment Answers				
Please circle your answers (one answer per question)				
1.	A	B	C	D
2.	A	B	C	D
3.	A	B	C	D
4.	A	B	C	D
5.	A	B	C	D
6.	A	B	C	D
7.	A	B	C	D
8.	A	B		
9.	A	B	C	D
10.	A	B	C	D
11.	A	B	C	D
12.	A	B	C	D
13.	A	B	C	D
14.	A	B	C	D
15.	A	B	C	D

**Program Evaluation – Must be completed for credit.**

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- 1. Overall quality of the article      1      2      3      4
- 2. Relevance to pharmacy practice    1      2      3      4
- 3. Value of the content                  1      2      3      4

*Please answer each question, marking whether you agree or disagree.*

- 4. This course met the learning objectives.     Agree    Disagree
- 5. The article did not promote a particular product or company.    Yes    No

**Impact of the Activity**

The information presented (check all that apply):

- 6.  Reinforced my current practice/treatment habits     Will improve my practice/patient outcomes  
 Provided new ideas or information I expect to use    Adds to my knowledge
- 7. Will the information presented cause you to make any changes in how you do your job?    Yes    No
- 8. How committed are you to making these changes?  
 (Not committed) 1    2    3    4 (Very committed).
- 9. Do you feel future activities on this subject matter are necessary and/or important?    Yes    No

**Follow-Up**

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

Yes    No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.